Objective. This pilot study clinically tests whether a conversion factor of 2 to 1 is appropriate
when changing from oral to parenteral morphine administration in the treatment of cancer …

Purpose: Several sustained-release morphine (SRM) formulations are available
internationally. This study compared 2 such products available in the United States, SR1 …

Cancer pain remains a worldwide problem and some patients continue to be
undermedicated because of concerns about tolerance and drug dependence. The aim of …

Background: Patients with cancer pain with initially adequate analgesia under oral
sustained-release opioid medication may suffer from persisting pain exacerbations …

To provide additional pharmacokinetic evidence for the oral-to-parenteral relative potency
ratio of 1: 2 to 1: 3 for chronic morphine use in a palliative care setting, we determined the …

Morphine (M) is the opioid analgesic of choice for severe cancer pain. The IV to PO M
equipotent switch ratio (CR) is controversial. We designed this prospective observational …

Objective: To investigate the serum concentrations of morphine, morphine-3-glucuronide
(M3G) and morphine-6-glucuronide (M6G) and the relationships between serum …

According to World Health Organization (WHO), cancer pain can be controlled effectively
with oral morphine in up to 90% of patients. Due to advancement in anticancer therapy and …

Objectives To evaluate whether the current European Association for Palliative Care
recommendation regarding the starting dose of 5 mg of normal-release morphine (NRM) …

Background Pain is one of the most common concomitant symptoms among cancer patients.
Pharmacologic agents are regarded as a cornerstone of cancer pain management.'Dose …